Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
about
CSAR 2014: A Benchmark Exercise Using Unpublished Data from Pharma.Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.Is there a role of synovial biopsy in drug development?Mechanisms of tissue damage in arthritis.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.
P2860
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
@ast
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
@en
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
@nl
type
label
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
@ast
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
@en
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
@nl
prefLabel
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
@ast
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
@en
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
@nl
P2860
P1433
P1476
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
@en
P2093
David L Scott
Ian C Scott
P2860
P2888
P304
P356
10.1007/S40265-014-0193-9
P577
2014-03-01T00:00:00Z
P6179
1003745936